Dror Yosef Abramov - 09 Feb 2025 Form 4 Insider Report for Silexion Therapeutics Corp (SLXN)

Role
Director
Signature
/s/ Mirit Horenshtein Hadar, Attorney-in-fact
Issuer symbol
SLXN
Transactions as of
09 Feb 2025
Net transactions value
$0
Form type
4
Filing time
31 Dec 2025, 13:13:15 UTC
Previous filing
15 Aug 2024
Next filing
23 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Abramov Dror Yosef Director 13 ZAMENHOF STREET, HERZLIYA, ISRAEL /s/ Mirit Horenshtein Hadar, Attorney-in-fact 31 Dec 2025 0002034083

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLXN Ordinary Shares Award $0 +794 $0.000000 794 09 Feb 2025 Direct F1, F2
holding SLXN Ordinary Shares 295 09 Feb 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLXN Stock Option (right to buy ordinary shares) Award $0 +935 $0.000000 935 09 Feb 2025 Ordinary Shares 935 $18.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents ordinary shares underlying RSUs granted to the Reporting Person by the Issuer. The shares subject to this award vest in full on the first anniversary of the date of grant, subject to the Reporting Person's continued service through such date.
F2 The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
F3 There were no transactions effected in respect of the ordinary shares reported in this row, and the holdings in this row are being included for informational purposes only.
F4 The number of ordinary shares reported in this row has been adjusted downwards to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
F5 The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.